DIH Holding US, Inc. Warrants
DHAIW
NASDAQ Global Market0.01
USD
+0.01
- -
CIK
0001883788
ISIN
US23290B1145
Return %
Stock
S&P500
1Y
-79.80
26.53
3Y
100,900.00
76.60
5Y
100,900.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lynden Bass
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 77 Accord Park Drive Norwell United States of America 02061
- IPO Date
- Feb 14, 2024
- CIK
- 0001883788
- Website
- dih.com
- Similar Companies
- Business
- DIH Holding US, Inc. provides robotics and virtual reality technology for physical rehabilitation to hospitals, clinics, research institutions, and home care settings worldwide, including Europe, the Middle East, Africa, the United States, and the Asia Pacific; its core products from brands Hocoma and Motek encompass upper extremity solutions such as ArmeoPower for early-stage arm and hand therapy, ArmeoSpring and ArmeoSpring Pro for self-initiated repetitive movements in extensive workspaces, and ArmeoSenso for transitioning to open movements; lower extremity devices including Erigo for verticalization, leg mobilization, and sensorimotor stimulation, Lokomat for robot-assisted gait training to build muscle strength and joint mobility, Andago for natural overground walking assistance, C-Mill for immersive training environments, CAREN as a computer-assisted rehabilitation system, and GRAIL for real-time gait analysis, training, and research; gait and balance systems like SafeGait, RYSEN, and M-Gait; plus software platforms HocoNet and D-Flow. Founded in 2007 and headquartered at 77 Accord Park Drive, Suite D-1, Norwell, Massachusetts, the company operates as a global distributor with five commercial regions, over 60 distributors, and approximately 221 employees, serving the medical devices segment of healthcare with a focus on neurorehabilitation, orthopedics, pediatrics, and sports medicine. Recent developments include a $22 million share purchase agreement in October 2025 to fund working capital and R&D in exoskeletons amid a 2.5% revenue decline but 8.4% service revenue growth for fiscal 2025; closure of a $4.6 million public offering of 5,937,100 units in 2025; expanded strategic partnership with Zahrawi Group (MTC Company) to cover Saudi Arabia; new partnership with Nobis Rehabilitation Partners to deploy Andago devices across their hospitals; appointments of Rehazentrum Valens, Shepherd Center, and Sheltering Arms Institute as DIH Centers of Excellence; board addition of Barrett Mooney, Ph.D., and scientific advisory board addition of Professor Nick Ward, M.D.; appointment of Dietmar Dold as Chief Operating Officer; and a 39% year-over-year Q2 2025 revenue increase to $18.2 million driven by 49% device sales growth primarily in EMEA, with updated fiscal 2025 guidance of $60 million to $67 million.